Litigation Details for Purdue Pharma, L.P. v. Collegium Pharmaceutical, Inc. - LEAD CASE (D. Mass. 2015)

Purdue Pharma, L.P. v. Collegium Pharmaceutical, Inc. - LEAD CASE (D. Mass. 2015)

Docket	1:15-cv-13099	Date Filed	2015-08-06
Court	District Court, D. Massachusetts	Date Terminated
Cause	35:145 Patent Infringement	Assigned To	F. Dennis Saylor IV
Jury Demand	Both	Referred To
Patents	7,674,799; 7,674,800; 7,683,072; 8,114,383; 9,073,933; 9,522,919
Link to Docket	External link to docket

Details for Purdue Pharma, L.P. v. Collegium Pharmaceutical, Inc. - LEAD CASE (D. Mass. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-08-06				External link to document
2015-08-06	1	Complaint	three API patents, U.S. Patent Nos. 7,674,799, 7,674,800, and 7,683,072 (“the Improved API patents”), are…claims 3 and 19 of U.S. Patent No. 7,674,799; claims 30-34 and 76-79 of U.S. Patent No. 7,674,800; claims…infringed U.S. Patent Nos. 7,674,799, 7,674,800, and 7,683,072 (“the Improved API patents”), and that the…right, title and interest in United States Patent No. 7,674,799 entitled “OXYCODONE HYDROCHLORIDE… infringement of U.S. Patent No. 8,652,497 (“the ‘497 Abuse-deterrence patent”), which relates to an	External link to document
2015-08-06	139		Invalidity And Non-Infringement Of U.S. Patent Nos. 9,073,933, 8,652,497, And 9,155,717, Defendant Collegium… 6 August 2015 1:15-cv-13099 830 Patent Defendant District Court, D. Massachusetts	External link to document

Purdue Pharma v. Collegium Pharmaceutical: Litigation Summary, Patent Analysis, and Xtampza ER Exclusivity

Last updated: August 31, 2026

Purdue Pharma’s action against Collegium Pharmaceutical concerned Collegium’s Xtampza ER extended-release oxycodone product and Purdue’s abuse-deterrent opioid patent estate. The case was filed in the U.S. District Court for the District of Massachusetts under lead case No. 1:15-cv-13099. The dispute arose from Collegium’s 505(b)(2) regulatory pathway and its proposed commercialization of Xtampza ER before expiration of Purdue patents covering controlled-release oxycodone and abuse-deterrent formulations.

The case was resolved through a court-approved dismissal rather than a reported merits judgment establishing broad infringement or invalidity precedent. Collegium ultimately commercialized Xtampza ER. The litigation therefore did not prevent market entry, but it created a patent and licensing risk around Collegium’s proprietary DETERx delivery technology.

What was Purdue Pharma v. Collegium about?

Purdue alleged that Collegium’s Xtampza ER product infringed Purdue patents covering abuse-deterrent controlled-release oxycodone formulations. Collegium disputed infringement and challenged the validity and enforceability of the asserted claims.

Xtampza ER contains oxycodone hydrochloride in a microsphere-based formulation. Collegium developed the product using its DETERx technology, which was designed to maintain extended release when the dosage form is manipulated and exposed to common abuse conditions.

Purdue’s complaint was filed before FDA approval of Xtampza ER. The litigation followed Collegium’s submission of a regulatory application seeking approval to market the product. The case was therefore structured as a Hatch-Waxman-style patent dispute, although Xtampza ER proceeded through the 505(b)(2) pathway rather than a conventional abbreviated new drug application.

Case identification

Item	Information
Case	Purdue Pharma, L.P. v. Collegium Pharmaceutical, Inc.
Court	U.S. District Court for the District of Massachusetts
Lead case number	1:15-cv-13099
Plaintiff	Purdue Pharma, L.P.
Defendant	Collegium Pharmaceutical, Inc.
Product	Xtampza ER
Active ingredient	Oxycodone hydrochloride
Dosage form	Extended-release oral capsules
Technology	Abuse-deterrent, extended-release microsphere formulation
Regulatory pathway	505(b)(2) NDA
Judge	Judge Rya W. Zobel
Principal dispute	Patent infringement, validity, and commercial launch of Xtampza ER

What patents did Purdue assert against Collegium?

Purdue’s asserted patent estate included patents directed to controlled-release oxycodone and abuse-deterrent dosage forms. The principal patents publicly associated with the case included U.S. Patent Nos. 8,337,886, 8,808,730, and 9,044,398.

Because patent assertions can change through amended pleadings, claim amendments, and narrowing during claim construction, the patent list should be read together with the operative complaint and subsequent court orders.

Purdue patent portfolio relevant to Xtampza ER

Patent	General subject matter	Relevance to litigation
U.S. Patent No. 8,337,886	Abuse-deterrent controlled-release opioid formulations	Core formulation and abuse-deterrence allegations
U.S. Patent No. 8,808,730	Abuse-deterrent opioid dosage forms	Related formulation and release characteristics
U.S. Patent No. 9,044,398	Controlled-release oxycodone and abuse-deterrent technology	Later-issued patent potentially relevant to amended assertions

The asserted claims generally addressed combinations of oxycodone, controlled-release components, physical properties, and resistance to tampering or dose extraction. The scope was narrower than a broad patent on oxycodone itself. The commercial risk therefore depended on whether Xtampza ER satisfied specific formulation and performance limitations in the asserted claims.

How did Xtampza ER differ from Purdue’s OxyContin technology?

Xtampza ER and OxyContin both contain extended-release oxycodone, but their delivery systems are different.

OxyContin uses a controlled-release tablet platform. Xtampza ER uses oxycodone-containing microspheres incorporated into capsules. Collegium’s formulation was designed to retain extended-release performance after crushing, chewing, or exposure to aqueous and alcoholic extraction conditions.

Attribute	OxyContin	Xtampza ER
Sponsor	Purdue Pharma	Collegium Pharmaceutical
Active ingredient	Oxycodone hydrochloride	Oxycodone hydrochloride
Dosage form	Extended-release tablet	Extended-release capsule
Delivery system	Controlled-release tablet matrix	Microsphere-based DETERx formulation
Abuse-deterrence approach	Physical and chemical properties of tablet formulation	Microsphere integrity and controlled-release performance
FDA product classification	Extended-release opioid analgesic	Abuse-deterrent extended-release opioid
Patent exposure	Purdue OxyContin and abuse-deterrent patents	Collegium DETERx and related formulation patents

The overlap was therefore based on functional and formulation limitations rather than identical dosage-form architecture. Purdue’s strongest theory depended on claim language broad enough to cover Xtampza ER’s abuse-deterrent and extended-release behavior.

What were the main legal issues in the case?

The litigation presented four principal issues: infringement, claim construction, patent validity, and the effect of Collegium’s 505(b)(2) application.

Infringement

Purdue’s infringement case required proof that Xtampza ER met each limitation of at least one asserted claim, either literally or under the doctrine of equivalents. The dispute likely centered on technical limitations involving:

• The structure of the controlled-release dosage form.
• The amount and distribution of oxycodone.
• The response of the formulation to crushing, chewing, or extraction.
• The relationship between abuse-deterrent properties and extended-release performance.
• Whether the claims covered microspheres rather than the tablet systems emphasized in Purdue’s earlier products.

Collegium’s principal defense was that its DETERx microsphere technology did not practice the required limitations of Purdue’s claims. A design-around position is particularly important in pharmaceutical formulation litigation because infringement cannot be established merely by showing that two products contain the same active ingredient or share a therapeutic use.

Claim construction

Claim construction was commercially significant because terms describing abuse-deterrent performance can materially affect infringement scope. The court was required to determine how a skilled person would understand formulation, release, and abuse-resistance limitations in light of the patent specifications and prosecution history.

For a formulation patent, seemingly narrow terms can determine whether a competitor’s product is inside or outside the claim. Terms related to “controlled release,” “abuse deterrence,” particle or microsphere structure, and drug extraction are often outcome-determinative.

Validity

Collegium challenged the asserted patents under the Patent Act, including obviousness and other invalidity grounds. The likely prior-art focus included:

• Earlier controlled-release oxycodone products.
• Abuse-deterrent opioid formulations.
• Microsphere and multiparticulate delivery systems.
• Published pharmaceutical formulation techniques.
• Purdue’s earlier patent disclosures and product development work.

The validity analysis turned on whether a skilled pharmaceutical formulator would have had a reason to combine known controlled-release and abuse-deterrent technologies with a reasonable expectation of success.

Regulatory pathway and patent certification

Xtampza ER was submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. A 505(b)(2) applicant may rely in part on FDA findings or published literature concerning an existing drug while providing new information supporting a modified formulation, dosage form, or delivery system.

The filing triggered patent litigation because Purdue sought to enforce patents that it believed covered the proposed product. The regulatory filing also affected the timing of approval, the 30-month stay framework, and the commercial launch strategy.

When did Collegium receive FDA approval for Xtampza ER?

The FDA approved Xtampza ER on April 26, 2016. The product was approved as an abuse-deterrent, extended-release oral formulation of oxycodone for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatments are inadequate.[1]

The approval did not eliminate Purdue’s patent claims. FDA approval and patent clearance are separate determinations. A product can receive FDA approval while remaining exposed to patent infringement litigation.

The FDA’s abuse-deterrent labeling also did not establish freedom from patent infringement. Abuse-deterrent labeling is based on FDA’s assessment of available laboratory, pharmacokinetic, and clinical data under its opioid abuse-deterrence guidance.

What was the outcome of Purdue Pharma v. Collegium?

The case ended without a reported final merits decision that invalidated Purdue’s patent estate or barred Xtampza ER from the market. The docket reflects termination through dismissal after the parties resolved the dispute.

The commercial result favored continued Collegium commercialization of Xtampza ER. The resolution avoided an injunction that could have delayed or stopped launch, while Purdue preserved the ability to manage its intellectual-property position through settlement and related patent rights.

Public docket materials do not provide a complete public accounting of the economic terms of the settlement. Accordingly, the record does not support treating the case as a reported royalty-rate precedent or as a judicial finding that Xtampza ER infringed every asserted Purdue patent.

Practical outcome

Issue	Result
FDA approval of Xtampza ER	Granted April 26, 2016
Market launch	Permitted to proceed
Purdue infringement claims	Resolved through dismissal
Reported invalidity ruling	None establishing broad invalidity
Permanent injunction against Collegium	None reported
Public settlement economics	Not fully disclosed in the dismissal record
Commercial effect	Collegium retained access to the Xtampza ER market

Was this a Paragraph IV challenge?

The dispute had the structure of a patent challenge connected to a 505(b)(2) filing, but the precise certification mechanics should not be confused with a standard ANDA Paragraph IV case.

A 505(b)(2) applicant may certify against listed patents in the Orange Book. Depending on the certification, the applicant may assert that the patent is invalid, unenforceable, or will not be infringed by the proposed product. The applicant’s notice can trigger patent litigation and a statutory stay of FDA approval.

The presence of patent litigation does not itself establish that the applicant made a Paragraph IV certification. The relevant regulatory documents and Orange Book certification records control that determination.

What was the Orange Book status of Purdue’s patents?

Purdue’s Orange Book position was relevant to the extent that the patents were listed against an FDA-approved oxycodone product and implicated the proposed Xtampza ER formulation. Orange Book listing is a regulatory mechanism that can support patent litigation, but it does not determine the ultimate scope or validity of a patent.

The key distinctions are:

1. Listing does not prove infringement.
2. FDA does not adjudicate patent validity.
3. A patent may be listed for one product while presenting a different infringement question for another dosage form.
4. Method-of-use listings generally present a different risk profile from formulation and composition listings.

The Xtampza ER dispute was principally a formulation and delivery-system dispute, not a simple method-of-use case. That distinction limited the relevance of broad oxycodone treatment patents and focused the litigation on technical product characteristics.

Did the case involve formulation patents or method-of-use patents?

The primary exposure involved formulation and abuse-deterrence claims. These patents can be more commercially significant than method-of-use patents because they may read directly on the product as manufactured and sold.

Formulation patent risk

Formulation claims can cover:

• Multiparticulate or microsphere structures.
• Release-control materials.
• Drug loading and particle-size ranges.
• Resistance to crushing or extraction.
• Extended-release profiles.
• Combinations of opioid and excipient components.

If a formulation patent is valid and infringed, a generic or competing 505(b)(2) product may need a redesign rather than a change to its proposed indication.

Method-of-use patent risk

Method-of-use patents generally cover administration of the drug for a specified disease, patient population, dosage schedule, or treatment objective. They can be addressed through a section viii-style labeling carve-out in an ANDA when the patented use is separable from unpatented uses.

That strategy is less useful against a formulation patent that covers the product itself. For Xtampza ER, the principal dispute was therefore more difficult to solve through labeling changes alone.

How strong was Purdue’s patent estate?

Purdue’s estate had meaningful commercial leverage because it was directed to abuse-deterrent opioid formulations, a category with regulatory value and limited technical substitutability. Its strength was constrained by several factors.

Strengths

• The patents addressed product architecture and performance rather than only the oxycodone molecule.
• Abuse-deterrent formulations require specialized formulation development and testing.
• A successful formulation patent can block a product despite the absence of composition-of-matter protection on the active ingredient.
• The patents were relevant to a regulated product category in which FDA labeling and abuse-deterrence claims carry commercial importance.

Weaknesses

• Controlled-release and multiparticulate delivery technologies had substantial prior art.
• The asserted claims required detailed technical proof.
• Xtampza ER used a microsphere platform that was materially different from a conventional controlled-release tablet.
• Purdue faced validity risk under obviousness standards.
• The patents did not create a perpetual barrier to oxycodone competition.

Purdue’s portfolio was therefore commercially credible but not immune from design-around and validity challenges. The settlement outcome indicates that both parties had incentives to avoid the cost and uncertainty of a final merits judgment.

What generic entry risks existed for Xtampza ER?

Generic entry risk for Xtampza ER was lower than the risk associated with an ordinary immediate-release oxycodone product because the product relied on a complex extended-release and abuse-deterrent formulation.

Principal barriers to generic entry

• Formulation complexity.
• Demonstration of bioequivalence.
• Replication of extended-release pharmacokinetics.
• Potential need to address abuse-deterrent labeling.
• Orange Book patent certifications.
• Exposure to formulation, process, and method-of-use patents.
• Potential FDA scrutiny of product sameness and substitutability.

A generic applicant could attempt a conventional ANDA if it could demonstrate the required pharmaceutical equivalence and bioequivalence. If it differed materially in formulation or delivery technology, a 505(b)(2) application could be more appropriate.

The patent risk would not be limited to the patents asserted in the lead case. Later-issued patents covering manufacturing processes, particle characteristics, capsule composition, release profiles, or specific abuse-deterrent properties could extend the practical exclusivity period.

What licensing and settlement issues affected the parties?

The resolution permitted Collegium to continue commercializing Xtampza ER. The settlement likely provided Purdue with contractual consideration and reduced litigation exposure for Collegium, but the complete economic terms were not made public in the court’s dismissal order.

For commercial diligence, the material questions are:

Diligence issue	Assessment
Continued sale of Xtampza ER	Permitted after resolution
Public license scope	Not fully detailed in the dismissal record
Royalty terms	Not reliably established by the public docket alone
Admission of infringement	Not established by the dismissal
Patent invalidity finding	Not established by the dismissal
Future patent disputes	Not necessarily eliminated by the settlement

A settlement in one patent action does not automatically release later-issued patents, unrelated patents, or disputes involving different products. Any freedom-to-operate conclusion must therefore be tied to the actual release and license language.

What litigation affected Xtampza ER after the lead case?

The lead case should be separated from later patent disputes involving Xtampza ER, Purdue’s opioid portfolio, and Collegium’s broader product line. Later patent filings can create new Orange Book and litigation exposure even after an earlier case is dismissed.

The commercial risk profile should be reviewed across four patent layers:

1. Active-ingredient patents, if any remain relevant.
2. Core formulation patents.
3. Manufacturing and process patents.
4. Method-of-use and labeling patents.

The first layer was weak by the time Xtampza ER entered the market because oxycodone was an established active ingredient. The second and third layers were more important for blocking a follow-on product.

How does Purdue v. Collegium compare with ordinary generic opioid litigation?

The case differed from a conventional generic challenge to a small-molecule product with a simple tablet formulation.

Factor	Conventional generic tablet case	Purdue v. Collegium
Applicant pathway	Usually ANDA	505(b)(2)
Main dispute	Bioequivalence and listed patents	Delivery technology and abuse-deterrent formulation
Design-around options	Often substantial	Technically difficult but available
Label carve-out	Sometimes effective	Less useful for product claims
FDA abuse-deterrent review	Usually absent	Central to product positioning
Manufacturing barrier	Moderate	Higher due to microsphere technology

The case illustrates why formulation patents can remain commercially important after composition-of-matter protection has expired. They do not protect the active ingredient broadly, but they can delay or complicate substitution with a therapeutically comparable product.

Key Takeaways

• Purdue sued Collegium over Xtampza ER, an abuse-deterrent extended-release oxycodone formulation.
• The lead case was filed in the District of Massachusetts under No. 1:15-cv-13099.
• Purdue’s asserted estate included patents directed to controlled-release and abuse-deterrent opioid formulations.
• Xtampza ER received FDA approval on April 26, 2016, through the 505(b)(2) pathway.
• Collegium used a microsphere-based DETERx delivery system rather than Purdue’s conventional controlled-release tablet platform.
• The case ended through dismissal after resolution, without a reported broad finding of infringement or invalidity.
• Collegium retained the ability to commercialize Xtampza ER.
• The principal patent risk involved formulation and delivery technology, not oxycodone as an active ingredient.
• Public court records do not establish complete settlement economics or a universal license to all Purdue patents.
• Follow-on diligence must include later-issued formulation, manufacturing, and method-of-use patents.

Frequently Asked Questions

What is the case number for Purdue Pharma v. Collegium Pharmaceutical?

The lead case number is 1:15-cv-13099 in the U.S. District Court for the District of Massachusetts.

What drug was at issue in the Purdue Collegium litigation?

The product was Xtampza ER, an extended-release oxycodone hydrochloride capsule developed and commercialized by Collegium Pharmaceutical.

Did Purdue stop Collegium from launching Xtampza ER?

No. Xtampza ER received FDA approval and was commercialized. The litigation did not result in a reported injunction preventing market entry.

Did the case establish that Xtampza ER infringed Purdue patents?

No reported final merits decision established that Xtampza ER infringed all asserted Purdue patents. The action was resolved through dismissal.

Are Xtampza ER patents still relevant after the Purdue settlement?

Yes. A settlement of the lead case does not necessarily resolve later-issued patents, unrelated patent families, manufacturing claims, or disputes outside the agreement’s release and license provisions.

References

1. U.S. Food and Drug Administration. (2016, April 26). FDA approves Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. https://www.fda.gov

2. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov

3. Purdue Pharma, L.P. v. Collegium Pharmaceutical, Inc., No. 1:15-cv-13099, U.S. District Court for the District of Massachusetts.

4. U.S. Patent No. 8,337,886. (2012). Abuse-deterrent controlled-release dosage forms. U.S. Patent and Trademark Office.

5. U.S. Patent No. 8,808,730. (2014). Abuse-deterrent opioid formulations. U.S. Patent and Trademark Office.

6. U.S. Patent No. 9,044,398. (2015). Controlled-release oxycodone formulations. U.S. Patent and Trademark Office.

7. Collegium Pharmaceutical, Inc. (2018). Annual report on Form 10-K. U.S. Securities and Exchange Commission.